ABOUT US
Kermode is an American privately-held, biotechnology company focused on solving the challenges of animal health. Our immediate focus is on livestock viruses such as African Swine Fever Virus (ASFV) and Swine Flu (SIV or S-OIV). Our current pipeline includes 2 products and is focused on both therapeutic antibodies and immune-stimulating vaccine proteins against ASFV:
KT100
ASFV vaccine
KT101
therapeutic antibody
ABOUT AFRICAN SWINE FEVER VIRUS
The spread ASFV has devastated the commercial swine industries in Europe, Russia, and most recently China, resulting in billions of lost dollars and the loss of a major nutritional staple. It is a matter of time before ASFV infiltrates North American livestock.
ASFV is a highly contagious viral pathogen that swiftly infects swine livestock.
Once the swine are infected, the virus will kill the animal within 24 to 48 hours.
The mortality rate for ASFV-infected animals is 100%.
OUR APPROACH
We are utilizing computational approaches to define vulnerable targets in viral structure, genetic composition and replication cycles. Once these targets are defined, we deploy state-of-the-art antibody discovery platforms to isolate therapeutic candidates with the highest potential to protect livestock against viral infections. This approach will allow Kermode to identify strong antibody therapeutics and construct vaccine candidates with long-lasting in vivo responses.
ASFV THERAPEUTIC DEVELOPMENT PIPELINE
ANTIBODY AND VIRAL PROTEIN DEVELOPMENT FOR THERAPEUTIC / VACCINE APPLICATIONS
Antibody & Protein Discovery
B/CHO
Hybrid
Ab
Amplify
Protein
Synthesis
Swine Animal Studies and Regulatory (Foreign)
Market
Approval
For therapeutic antibody vaccine and protein vaccine
ASFV THERAPEUTIC DEVELOPMENT PIPELINE
ANTIBODY AND VIRAL PROTEIN DEVELOPMENT FOR THERAPEUTIC / VACCINE APPLICATIONS
- Antibody & Protein Discovery
- B/CHO Hybrid
- Ab Amplify
- Protein Synthesis
- Swine Animal Studies and Regulatory (Foreign)
- Market Approval
- For therapeutic antibody vaccine and protein vaccine
BOARD OF DIRECTORS
Kermode’s corporate governance is monitored through experienced biotechnology professionals with deep experience in the field.
Dan Chen, MBA
Tom Malcolm, PhD
Safia Rizvi, PhD
Heng Xie, PhD
OUR TEAM
Our goal is to provide an exceptional level of research, and we aim for lasting partnerships with our partners and our global communities.
Dan Chen, MBA
Founder & CEO
Tom Malcolm, PhD
Founder & COO
Ed Robb, DVM, MS, DACVN
Chief of Regulatory and Veterinarian Affairs
Jeff Chen, MBA
Business Operations, China
Tony Chen, PhD
CSO
Ken Kohn, PhD
EVP of Licensing Operations
PARTNERS
INVESTORS & PARTNERS
Access our technical approaches and detailed pipeline information